REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat reports. One research analyst ...
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...
GlobalData on MSN22h
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapyRegenxbio has revealed plans to submit a biologics licence application (BLA) for RGX-202, its investigational gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback